Navigation Links
SomaLogic and Ambergen announce agreement for commercial applications of photocleavable biotin
Date:11/29/2011

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscanTM technology platform.

The biggest constraint on successful development of a high-throughput proteomic quantitation platform is achieving sufficient sensitivity. SomaLogic's innovative SOMAmer (Slow Off-rate Modified Aptamer) protein-capture reagents and their multiplex SOMAscan technology break through this limitation.

AmberGen has developed a range of novel molecules and compounds with photocleavable linkers, including a 5-prime photocleavable biotin, a light-activated biomolecule that it has licensed to SomaLogic. "AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our SOMAscan platform" said Nick Saccomano, Ph.D., Chief Technology Officer at SomaLogic.

The SOMAscan technology platform utilizes SOMAmers to accurately screen dozens of patient samples simultaneously, allowing quantification of many specific proteins in a multiplexed, high-throughput manner. SomaLogic has thus far validated SOMAmers to a broad array of over 1000 different protein targets for use in biomarker discovery, diagnostics, and drug discovery and development.

"We look forward to exploring new applications for our photocleavable technologies with SomaLogic, as we continue to support their existing and emerging SOMAmer reagents," stated Christopher Sears, Ph.D., Chief Scientific Officer of AmberGen. "With both companies' commitment to developing tools for personalized medicine, there are ample opportunities for further collaboration."


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
617-816-9834
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic announces agreement with leading global pharma company to accelerate R&D
2. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
3. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
4. EpiGen announces collaboration with Nestlé
5. Minister announces UK-India collaboration on bioenergy
6. BGI announces collaborative research agreements with Oregon State University
7. NIH TRND program announces next round of drug development projects
8. DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers
9. BGI announces collaboration with Johns Hopkins University on synthetic yeast project
10. Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
11. Childrens Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: